IHC - Mammaglobin

The IHC – Mammaglobin test is a specialized immunohistochemistry (IHC) diagnostic test used to detect Mammaglobin protein expression in tissue samples. Mammaglobin is a protein commonly produced by breast epithelial cells and is considered an important marker for identifying tumors of breast tissue origin.

This test is widely used in pathology laboratories to help diagnose primary breast carcinoma and confirm whether metastatic tumors in other organs originated from breast tissue. Mammaglobin is highly useful when evaluating cancers of unknown primary origin, especially in patients with a history of breast cancer or suspicious metastatic lesions.

The Mammaglobin test is often performed along with other breast cancer markers such as ER, PR, HER2/neu, and GCDFP-15 to improve diagnostic accuracy and provide comprehensive tumor profiling.

Benefits of the Test

The Mammaglobin IHC test offers several clinical benefits:

• Detects breast tissue-specific protein expression
• Helps confirm breast-origin tumors
• Supports diagnosis of metastatic breast carcinoma
• Differentiates breast tumors from other cancers
• Improves tumor classification accuracy
• Assists in treatment planning and prognosis evaluation

This test is especially valuable when tumor origin is uncertain under routine microscopic examination.

Why Doctors Recommend This Test

Doctors recommend the Mammaglobin IHC test when breast cancer is suspected or when metastatic cancer needs confirmation of breast origin.

It is commonly advised for:

• Suspected primary breast carcinoma
• Metastatic tumors of unknown primary site
• Patients with previous breast cancer history
• Tumor recurrence evaluation
• Detailed breast cancer profiling

The results help oncologists determine the source of metastatic cancer and guide personalized treatment decisions.

Preparation Before Test

No special preparation is required from the patient. The test is performed on tissue biopsy or surgically removed specimens already collected during diagnostic procedures.

Normal Reporting Time

The normal turnaround time for the Mammaglobin IHC test is 2 to 4 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected breast cancer
• Individuals with metastatic tumors of unclear origin
• Patients with recurrent breast carcinoma
• Cases needing confirmation of breast tissue origin
• Oncology patients requiring advanced tumor marker analysis

The IHC Mammaglobin test is an essential diagnostic tool in breast cancer pathology. It helps confirm breast-origin tumors accurately and supports timely diagnosis, precise treatment planning, and improved patient outcomes.